{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:32:10Z","timestamp":1787754730732,"version":"build-2784847793"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["HNO"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00106-026-01769-7","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T15:08:00Z","timestamp":1780412880000},"page":"635-646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["S2k-Leitlinie Antibiotikatherapie von HNO-Infektionen","German S2k guideline on antibiotic therapy of ENT infections"],"prefix":"10.1007","volume":"74","author":[{"given":"Bernhard","family":"Olzowy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"1769_CR1","unstructured":"(2025) S2k-Leitlinie Antibiotikatherapie von HNO-Infektionen. https:\/\/register.awmf.org\/assets\/guidelines\/017-066l_S2k_Antibiotikatherapie-bei-HNO-Infektionen_2025-09.pdf. Accessed 14.12.2025"},{"key":"1769_CR2","doi-asserted-by":"crossref","unstructured":"Maxfield, A.Z., et\u00a0al., General antibiotic exposure is associated with increased risk of developing chronic rhinosinusitis. Laryngoscope, 2016.","DOI":"10.1002\/lary.26232"},{"issue":"7","key":"1769_CR3","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/cid\/cix947","volume":"66","author":"J Baggs","year":"2018","unstructured":"Baggs\u00a0J et\u00a0al (2018) Risk of Subsequent Sepsis Within 90 Days After a Hospital Stay by Type of Antibiotic Exposure. Clin Infect Dis 66(7):1004\u20131012","journal-title":"Clin Infect Dis"},{"key":"1769_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jpeds.2022.07.053","volume":"251","author":"HM Frost","year":"2022","unstructured":"Frost\u00a0HM et\u00a0al (2022) Amoxicillin Versus Other Antibiotic Agents for the Treatment of Acute Otitis Media in Children. J\u00a0Pediatr 251:98\u2013104","journal-title":"J Pediatr"},{"issue":"1","key":"1769_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.anai.2021.07.005","volume":"128","author":"A Piotin","year":"2022","unstructured":"Piotin\u00a0A et\u00a0al (2022) Predictive factors of amoxicillin immediate hypersensitivity and validation of PEN-FAST clinical decision rule. Ann Allergy Asthma Immunol 128(1):27\u201332","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"5","key":"1769_CR6","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1001\/jamainternmed.2020.0403","volume":"180","author":"JA Trubiano","year":"2020","unstructured":"Trubiano\u00a0JA et\u00a0al (2020) Development and Validation of a Penicillin Allergy Clinical Decision Rule. JAMA Intern Med 180(5):745\u2013752","journal-title":"JAMA Intern Med"},{"issue":"1","key":"1769_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-025-01894-z","volume":"51","author":"G Castelli Gattinara","year":"2025","unstructured":"Castelli Gattinara\u00a0G et\u00a0al (2025) Antibiotic treatment of acute and recurrent otitis media in children: an Italian intersociety Consensus. Ital J Pediatr 51(1):50","journal-title":"Ital J Pediatr"},{"key":"1769_CR8","unstructured":"(2024) S3-Leitlinie Perioperative und Periinterventionelle Antibiotikaprophylaxe. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/067-009. Accessed 4.1.2026"},{"key":"1769_CR9","unstructured":"e.\u202fV., P.-E.-G.f.I. Resistenzdaten (2022) Resistenzdaten. https:\/\/www.p-e-g.org\/resistenzdaten.html. Accessed 4.1.2026"},{"key":"1769_CR10","unstructured":"(2019) Rote-Hand-Brief zu Fluorchinolon-Antibiotika: Schwerwiegende und anhaltende, die Lebensqualit\u00e4t beeintr\u00e4chtigende und m\u00f6glicherweise irreversible Nebenwirkungen. https:\/\/www.bfarm.de\/SharedDocs\/Risikoinformationen\/Pharmakovigilanz\/DE\/RHB\/2019\/rhb-fluorchinolone.html. Accessed 10.1.2025"},{"key":"1769_CR11","volume":"8","author":"B Olzowy","year":"2020","unstructured":"Olzowy\u00a0B et\u00a0al (2020) Calculated parenteral initial treatment of bacterial infections: Infections in the ear, nose, throat and mouth and jaw area. GMS Infect Dis 8:Doc14","journal-title":"GMS Infect Dis"},{"issue":"3","key":"1769_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s00431-014-2409-0","volume":"174","author":"M van der Linden","year":"2015","unstructured":"van der Linden\u00a0M et\u00a0al (2015) Bacterial spectrum of spontaneously ruptured otitis media in the era of pneumococcal conjugate vaccination in Germany. Eur J Pediatr 174(3):355\u2013364","journal-title":"Eur J Pediatr"},{"issue":"Suppl S29","key":"1769_CR13","first-page":"1","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens\u00a0WJ et\u00a0al (2020) European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology 58(Suppl S29):1\u2013464","journal-title":"Rhinology"},{"key":"1769_CR14","unstructured":"(2024) S3-Leitlinie Therapie der Tonsillo-Pharyngitis. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/017-024. Accessed 12.1.2025"},{"key":"1769_CR15","unstructured":"(2020) S3-Leitlinie Halsschmerzen. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/053-010. Accessed 5.1.2026"},{"key":"1769_CR16","unstructured":"(2023) Empfehlungen f\u00fcr die Wiederzulassung zu Gemeinschaftseinrichtungen gem\u00e4\u00df \u00a7\u00a034 Infektionsschutzgesetz.. Accessed 12.1.2025"}],"container-title":["HNO"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-026-01769-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00106-026-01769-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00106-026-01769-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:31:37Z","timestamp":1787751097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00106-026-01769-7"}},"subtitle":["Das Wichtigste in K\u00fcrze","The most important information in brief"],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":16,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1769"],"URL":"https:\/\/doi.org\/10.1007\/s00106-026-01769-7","relation":{},"ISSN":["0017-6192","1433-0458"],"issn-type":[{"value":"0017-6192","type":"print"},{"value":"1433-0458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"21 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":1,"name":"Ethics","label":"Interessenkonflikt","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"B.\u00a0Olzowy\n                      : A.\u00a0Finanzielle Interessen: zahlreiche honorierte Vortr\u00e4ge direkt zum Thema \u201eAntibiotika\u201c bzw. diversen Infektionserkrankungen | honoriert durch die Fortbildungsgesellschaft der HNO-\u00c4rzte: Vortrag (Webinar) Antibiotikatherapie 24.09.2020, Vortrag Antibiotic Stewardship 28.10.2021, Kursleitung Antibiotikatherapie 27.10.2022; Rundtisch Geh\u00f6rgangsentz\u00fcndungen\u00a0\u2013 Neue Ans\u00e4tze bei komplizierten F\u00e4llen \u201eBakterielle Geh\u00f6rgangsentz\u00fcndungen\u201c Okt. 2023; Vortrag \u201eDiese Studien ver\u00e4ndern meine Arbeit\u00a0\u2013 Rhinologie\u201c 01.11.2024; Vortrag S2k-Leitlinie \u201eAntibiotikatherapie von HNO-Infektionen\u201c 30.10.2025; Rundtisch komplexe Mittelohrprobleme \u201eRezidivierende Otitis media\u201c 31.10.205; honoriert durch InfectoPharm: Vortrag Antibiotikatherapie 11.02.2023; Vortrag \u201eLokaltherapie entz\u00fcndlicher Ohrerkrankungen\u201c 24.02.2024; Vortrag \u201eAkute Rhinosinusitis\u201c 14.02.2026; honoriert durch RG \u00c4rztefortbildung: Vortrag (Webinar) Antibiotikatherapie 22.06.2020, Vortrag Therapie der chronischen Sinusitis 17.07.2021; honoriert durch die Akademie f\u00fcr Infektionsmedizin: Vortr\u00e4ge Sinusitis, Otitis media 19.03.2022; honoriert durch MMW\/Springer: Atemwegsinfektionen in der Praxis 13.11.2024; honoriert durch Medical Tribune: Vortrag \u201eAntiseptische und entz\u00fcndungshemmende Wirkstoffe zur Behandlung von Halsschmerzen\u201c 27.09.2025.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Niedergelassener HNO-Arzt, HNO-Zentrum Landsberg, Landsberg am Lech | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr HNO-Heilkunde, Kopf- und Hals-Chirurgie; 2021\u20132025 Vorsitzender der AG Infektiologie und Hygiene der Dt. Gesellschaft f\u00fcr HNO-Heilkunde, Kopf- und Hals-Chirurgie; Deutscher Berufsverband der Hals-Nasen-Ohren\u00e4rzte; Paul-Ehrlich-Gesellschaft f\u00fcr Infektionstherapie; Berufenes Mitglied der Kommission Antiinfektiva, Resistenz und Therapie (Kommission ART) beim Robert Koch-Institut (RKI).","order":2,"name":"Ethics","label":"Autorinnen und Autoren","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":3,"name":"Ethics","label":"Wissenschaftliche Leitung","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":4,"name":"Ethics","label":"Der Verlag","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}}]}}